My first @Pharma_GD not behind their paywall 👀 clinicaltrialsarena.com/comment/alkerm…

I wrote about how a rare Medicare process could affect uptake of the controversial Alzheimer's drug Aduhelm clinicaltrialsarena.com/analysis/aduhe…

.@ArenaClinical – #BioMarin's #vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for #achondroplasia, the most common form of short-limbed #dwarfism. bit.ly/3rWxqSY

Wrote about the incomplete safety data for Aduhelm, the recently FDA-approved Alzheimer’s disease drug bit.ly/adusafety

Will Newton and my story on how Merck and Ridgeback’s #molnupiravir rollout will be difficult to map in an uncertain Covid-19 landscape. While the field figures out the oral antiviral's safety profile the initial emphasis may be on high-risk people clinicaltrialsarena.com/analysis/molnu… $mrk

Schizophrenia drug landscape: a stagnant field on the cusp of change? Will Newton talks to experts about Sunovion’s ulotaront, Minerva’s roluperidone, and Teva and MedinCell’s extended-release risperidone $SEPR $TEVA $MDCLF $NERV clinicaltrialsarena.com/analysis/schiz…

Clinical Trials Arena's William Newton (Will Newton) caught up with Annovis Bio CEO Maria Maccecchini (Maria L. Maccecchini, PhD). She gave us a sneak peek at the company's Phase III trial blueprint for ANVS401 in Alzheimer’s and Parkinson’s disease $ANVS clinicaltrialsarena.com/analysis/annov…

Platform trials can streamline rare disease research by testing multiple treatments & diseases under one protocol. Will Newton reports on the upside and challenges of this innovative trial design, and its potential in rare dystrophies and gene therapies clinicaltrialsarena.com/features/platf…

In an exclusive, @medicagoinc previews its blueprint for a booster trial of its Covid-19 vaccine candidate slated for January, Will Newton reports #Medicago clinicaltrialsarena.com/news/company-n…

Differing endpoint and efficacy expectations can make designing an ALS clinical trial challenging. Will Newton talked to KOLs and found ways to damped drug development obstacles clinicaltrialsarena.com/analysis/mappi…

I wrote about how e-commerce pharmacies are attempting to cut soaring insulin prices, and the challenges they face, including insulin black markets: pharmaceutical-technology.com/features/insul…

NeuroSense CEO Alon Ben-Noon previews an upcoming Phase IIb trial in #ALS with reporter Will Newton. Read more about the target patient population, trial endpoints, and timeline here: clinicaltrialsarena.com/news/neurosens…

Some ultra-rare diseases have fewer than 30 known patients globally and almost no available treatments. I spoke to researchers, regulators and bioethicists on new strategies to test and approve drugs for ultra-rare conditions:

On International Clinical Trials Day, we have a feature on Dengue fever, on the struggle to develop antivirals and vaccines. Reporting by Will Newton clinicaltrialsarena.com/analysis/dengu…

There is still no specific treatment for #dengue, despite 390 million yearly infections - a number that is rising. Our #DrugDiscovery Director Charles Mowbray & other researchers reflect on how to overcome drug development obstacles. Clinical Trials Arena #5thADS bit.ly/3mBTqjW

After #ASCO22 focused on the need for more diversity in cancer clinical trials, I wrote about how experts are leveraging data to improve trial recruitment and design for Clinical Trials Arena clinicaltrialsarena.com/analysis/diver…

I asked Dr. Fauci about the challenges of studying long Covid in clinical trial, and heard his takes on Covid misinformation and public perception: clinicaltrialsarena.com/special-focus/…

I spent the last month writing a piece on the future of medicine in outer space! I spoke to researchers about designing drug trials on the ISS, studying how humans respond to cosmic radiation, synthesizing artificial medicine for a Mars mission, and more: clinicaltrialsarena.com/analysis/medic…